CTLA4 and melanoma: The combination of anti-CTLA-4 monoclonal antibodies, anti-PD-L1 monoclonal antibodies, and the IDO inhibitor INCB23843 in the murine B16.SIY melanoma model showed markedly improved tumor control over single-drug treatment [26].